Abby's

Volume 9, Issue 2

Issue link: http://cp.revolio.com/i/1386959

Contents of this Issue

Navigation

Page 23 of 35

Page 24 | Abby's Magazine | www.AbbysMag.com Many doctors around the world started using the an -malaria drug hydroxychloroquine (HCQ) early on in the COVID-19 pandemic. Among them is Dr. Vladimir Zelenko, a prac cing physician in a Jewish community in Monroe, New York. He garnered na onal a en on in March 2020 when he told radio host Sean Hannity that he'd had a near-100% success rate trea ng COVID-19 pa ents with HCQ, azithromycin and zinc sulfate for five days. "I've seen remarkable results; it really prevents progression of disease, and pa ents get be er," he said at the me. "When we have a large popula on of people that need to be treated, it has to be oral, cheap, safe and effec ve," he says. "By the way, this is not new. This informa on was known in 2005 — even before. There are papers with [Dr. Anthony] Fauci's name on it, calling [HCQ] a miracle drug. Fauci called HCQ a vaccine. There's a paper in which he called it an absolute dream treatment and vaccine. So, it's conveniently forgo en but that's what it is. It's a ma er of scien fic record." Finding Solutions to Avoid a Death Trap As the SARS-CoV-2 swept through his ght-knit Jewish community, Zelenko was seeing anywhere from 50 to 250 pa ents per day. At this point, he's treated more than 3,000 pa ents with COVID-19- related symptoms. Only one-third of them actually received the triple-drug regimen. The remaining two-thirds were in low-risk categories and did not need drug treatment. In all, Zelenko has only had 15 pa ents who ended up requiring hospitaliza on, four of whom were intubated. All were eventually successfully extubated and recovered. The remaining 11 were admi ed for intravenous an bio cs for pneumonia. In all, only three of his high-risk pa ents died from COVID-19, which puts the mortality rate for this treatment at just 0.3%. "You cannot ignore that. That's not even coun ng the risk stra fica on pa ents, which I chose not to treat. In other words, I was able to tell these pa ents, 'I know you're going to be fine. Go home, and you'll be fine.' And that has value. If you include those, the mortality rate is even less. And this has been reproduced. You don't have to listen to me. You can call it anecdotal all you want, but there are now Harvard professors of virology with 4,000 pa ent experiences. Dr. George Fareed, for example, or Dr. Harvey Risch from Yale School of Epidemiology, who has shown that it's absolutely sta s cally proven that HCQ used in the prehospital se ng is absolutely effec ve. It's impossible for it to be a mistake," he says. Why HCQ? Zelenko se led on HCQ, a so-called zinc ionophore, meaning it shu les zinc into the cell. He decided to treat high-risk pa ents as early as possible, and this turned out to be key. Early treatment really saves lives when it comes to COVID-19. This is not a situa on where the wait-and-see strategy is well-advised. According to Zelenko, during the first five days of SARS-CoV-2 infec on, the viral load remains fairly steady. Around Day 5, it exponen ally increases, poten ally overwhelming the immune system. This also meant he could not afford to wait for test results, which took about five days. By then, most pa ents would already have progressed too far. So, if a pa ent exhibited symptoms, especially if they reported loss of taste or smell as well, he'd start treatment immediately. In hindsight, about 90% of the tests of people experiencing symptoms had a posi ve test. e Synergy of HCQ and Zinc Zelenko likens HCQ and zinc like a gun and a bullet. HCQ is the gun that shoots the zinc into the cell. Zinc is the silver bullet NY Doctor Proved Everyone Wrong About Analysis By Dr. Joseph Mercola Hydroxychloroquine

Articles in this issue

Links on this page

Archives of this issue

view archives of Abby's - Volume 9, Issue 2